Gutierrez, AntonioBento, LeyreNovelli, SilvanaMartin, AlejandroGutierrez, GonzaloQueralt Salas, MariaBastos-Oreiro, MarianaPerez, AriadnaHernani, RafaelCruz Viguria, MariaLopez-Godino, OrianaMontoro, JuanPiñana, Jose LuisFerra, ChristelleParody, RocioMartin, CarmenEspañol, IgnacioYañez, LucreciaRodriguez, GuillermoZanabili, JoudHerrera, PilarVarela, Maria RosarioSampol, AntoniaSolano, CarlosCaballero, Dolores2023-05-032023-05-032022-05-27Gutierrez A, Bento L, Novelli S, Martin A, Gutierrez G, Queralt Salas M, et al. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. Cancers (Basel). 2022 May 27;14(11):26732072-6694http://hdl.handle.net/10668/20899Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/CAR-T cell therapyAcute graft-versus-host diseaseAllogeneic stem-cell transplantationGraft-versus-lymphoma effectMantle cell lymphomaNon-relapse mortalityTarget therapySiblingsChronic DiseaseGraft vs Host DiseaseNeoplasm Recurrence, LocalTransplantation Conditioningresearch article35681653open accessDonantes de tejidosHermanosEspaña10.3390/cancers14112673PMC9179246https://www.mdpi.com/2072-6694/14/11/2673/pdf?version=1653666523https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179246/pdf